Pittsburgh, PANCT05157581Now EnrollingIRB Ready

Sezary Syndrome Clinical Trial in Pittsburgh, PA

Access cutting-edge sezary syndrome treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by Oleg E. Akilov, MD, PhD

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access sezary syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sezary syndrome treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this sezary syndrome clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Sezary Syndrome Study in Pittsburgh

The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 20 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months. Each patient will donate 5 samples to determine immune responses in peripheral blood. Additional clinical assessments will be a modified skin weighted assessment and flow cytometry at baseline and months 3 and 6. A CT scan will be obtained at baseline and only repeated if pathology is present at baseline. The tumor microenvironment will be studied by comparing transcriptomics of the blood samples before, 1 day after first ECP treatment, cycle 1, 1, 3 and 6 months after ECP treatment by scRNAseq (5 samples total per patient ).

Sponsor: Oleg E. Akilov, MD, PhD

Who Can Participate

Inclusion Criteria

Patient with an established diagnosis of Sezary syndrome (stage IVA1)
Patients amenable for ECP
The patient must have a minimum wash-out period of 3 weeks between the last dose of prior systemic therapy
Patients should have recovered from all adverse events related to prior therapy to ≤ grade 1
Signed informed consent form prior to any protocol-specific procedures.

Exclusion Criteria

Visceral metastasis of lymphoma
Concomitant administration of radiotherapy or systemic anti-cancer therapy including but not restricted to: chemotherapy, biological agents, or immunotherapy
Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection.
Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol.
Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.
Patients with known allergy to Methoxsalen or heparin (as part of SOC ECP procedure).
Patients who are pregnant. -

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT05157581) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sezary Syndrome Treatment Options in Pittsburgh, PA

If you're searching for sezary syndrome treatment options in Pittsburgh, PA, this clinical trial (NCT05157581) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sezary syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sezary syndrome clinical trials near you to find additional studies recruiting in your area.

More Myalgic Encephalomyelitis Trials in Pittsburgh, PA

See all myalgic encephalomyelitis clinical trials recruiting in Pittsburgh — not just this study.

Browse Myalgic Encephalomyelitis Trials in Pittsburgh

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA